When compared to the non-engineered type, OVV-CD19BiTE can recruit more CD3, CD8, and naïve CD8 T subpopulations to tumor tissues, while retaining similar ability to replicate in and lyse tumor cells (116). This evidence concerns the gene CD8A and neoplasm.